These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8724792)

  • 1. What are the risks of third-generation oral contraceptives? Are third-generation oral contraceptives safe?
    Rosenberg L; Bégaud B; Bergman U; Brown B; Buist AS; Cramer D; Daling J; Grimes D; Kemper F; Mills A
    Hum Reprod; 1996 Apr; 11(4):687-8. PubMed ID: 8724792
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral contraceptives and myocardial infarction: results of the MICA case-control study.
    Dunn N; Thorogood M; Faragher B; de Caestecker L; MacDonald TM; McCollum C; Thomas S; Mann R
    BMJ; 1999 Jun; 318(7198):1579-83. PubMed ID: 10364115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Spitzer WO; Heinemann LA; MacRae KD; Bruppacher R; Thorogood M
    BMJ; 1996 Jan; 312(7023):88-90. PubMed ID: 8555936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebuilding confidence in oral contraceptives: a new imperative in family planning.
    Spitzer WO
    Br J Clin Pharmacol; 1996 May; 41(5):359-63. PubMed ID: 8735675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-generation oral contraceptives and venous thrombosis.
    Grant EC
    Lancet; 1997 Mar; 349(9053):733. PubMed ID: 9078228
    [No Abstract]   [Full Text] [Related]  

  • 7. Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives.
    Boef AG; Souverein PC; Vandenbroucke JP; van Hylckama Vlieg A; de Boer A; le Cessie S; Dekkers OM
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):317-24. PubMed ID: 26749045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined oral contraceptive. Risks and adverse effects in perspective.
    Bagshaw S
    Drug Saf; 1995 Feb; 12(2):91-6. PubMed ID: 7766340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Third generation oral contraceptives and risk of venous thrombosis--the English lesson].
    Sørensen MB
    Ugeskr Laeger; 2002 Apr; 164(18):2418; author reply 2418-9. PubMed ID: 12024851
    [No Abstract]   [Full Text] [Related]  

  • 10. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database.
    Farmer RD; Williams TJ; Simpson EL; Nightingale AL
    BMJ; 2000 Aug 19-26; 321(7259):477-9. PubMed ID: 10948026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation oral contraceptives containing desogestrel and gestodene and the risk of thrombosis.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):5-7. PubMed ID: 8920631
    [No Abstract]   [Full Text] [Related]  

  • 13. Third generation oral contraceptives and the risk of pulmonary embolism.
    Egermayer P
    N Z Med J; 1999 Nov; 112(1100):455. PubMed ID: 10678249
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraception and venous thromboembolism. A New Zealand perspective.
    Roke C
    Drug Saf; 1997 Feb; 16(2):79-87. PubMed ID: 9067120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism'.
    Terplan M; Zuckerman D
    J Fam Plann Reprod Health Care; 2013 Oct; 39(4):304. PubMed ID: 24062505
    [No Abstract]   [Full Text] [Related]  

  • 17. Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis?
    Sapp AV; Lindbloom EJ
    J Fam Pract; 2001 Oct; 50(10):893. PubMed ID: 11674894
    [No Abstract]   [Full Text] [Related]  

  • 18. Third-generation oral contraceptives and venous thrombosis.
    Vandenbroucke JP; Helmerhorst FM; Bloemenkamp KW; Rosendaal FR
    Lancet; 1997 Mar; 349(9053):731; author reply 732-3. PubMed ID: 9078225
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of CSM's warning about safety of third generation oral contraceptives. Contraceptive effectiveness may be being sacrificed for safety.
    Murty J; Firth S
    BMJ; 1996 Aug; 313(7053):363. PubMed ID: 8760759
    [No Abstract]   [Full Text] [Related]  

  • 20. Exercise-induced fibrin formation is enhanced in women using third-generation oral contraceptives.
    Walter B; Weiss C; Dorsch M; Bärtsch P
    J Thromb Haemost; 2006 Apr; 4(4):898-9. PubMed ID: 16634763
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.